Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...
Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...
The FDA approved the PI3K-pathway inhibitor inavolisib (Itovebi) for use in combination with palbociclib (Ibrance) and fulvestrant to treat locally advanced, PIK3CA ...
Acquisition of Faeth and concurrent $200 million private investment positions the combined company to advance its pipeline across key clinical milestones in endometrial and breast cancerPIKTOR is an ...
Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company. | Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling ...
Investing.com -- Sensei Biotherapeutics (NASDAQ:SNSE) stock soared 200% Wednesday after the company announced its acquisition ...
Sensei Biotherapeutics, Inc. SNSE surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment. The ...
Presentation Details Conference: ESMO Targeted Anticancer Therapies (TAT) Congress 2026 Session: Oral Presentation Date: Monday, March 16, 2026 at 16:20 Presenter: Antonio Giordano, MD, PhD, Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results